Press releases

Pharmaceutical study starts in Sweden with BAN2401 in early Alzheimer patients

May 12, 2014 - Other press release

BioArctic Neuroscience AB today announced that the first patient in Sweden has been treated with BAN2401 in a clinical study aimed at patients with an early ...

Pharmaceutical study starts in Sweden with BAN2401 in early Alzheimer patients

Jan Mattsson

Vice President Finance, Chief Financial Officer

jan.mattsson@bioarctic.se

+46 703 52 27 72

Proud partner of: